Literature DB >> 15671355

Temporary occlusion of two hepatic veins for chemoembolization of hepatocellular carcinoma with arteriohepatic vein shunts.

Satoru Murata1, Hiroyuki Tajima, Yutaka Abe, Tsuyoshi Fukunaga, Ken Nakazawa, Rabie Abdul Aziz Mohamad, Tatsuo Kumazaki.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671355     DOI: 10.2214/ajr.184.2.01840415

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


× No keyword cloud information.
  5 in total

1.  Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shunts.

Authors:  Satoru Murata; Hiroyuki Tajima; Ken Nakazawa; Shiro Onozawa; Shinichiro Kumita; Kazuhiro Nomura
Journal:  Eur Radiol       Date:  2009-02-24       Impact factor: 5.315

Review 2.  Interventional treatment for unresectable hepatocellular carcinoma.

Authors:  Satoru Murata; Takahiko Mine; Fumie Sugihara; Daisuke Yasui; Hidenori Yamaguchi; Tatsuo Ueda; Shiro Onozawa; Shin-ichiro Kumita
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

3.  Advanced Hepatocellular Carcinoma With Hepatic Arterioportal Shunts: Combination Treatment of Transarterial Chemoembolization With Apatinib.

Authors:  Tao Sun; Yanqiao Ren; Xuefeng Kan; Lei Chen; Weihua Zhang; Fan Yang; Chuansheng Zheng
Journal:  Front Mol Biosci       Date:  2020-12-04

Review 4.  A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma.

Authors:  Hossein Ghanaati; Mahyar Mohammadifard; Mahtab Mohammadifard
Journal:  J Family Med Prim Care       Date:  2021-11-05

Review 5.  Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma.

Authors:  Satoru Murata; Takahiko Mine; Tatsuo Ueda; Ken Nakazawa; Shiro Onozawa; Daisuke Yasui; Shin-ichiro Kumita
Journal:  ScientificWorldJournal       Date:  2013-03-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.